AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 11 min read

Adagio Medical Holdings, Inc. (ADGM): Unregistered Sales of Equity Securities

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed in Adagio Medical Holdings, Inc.’s (the “Company”) Current Report on Form 8-K filed on September 23, 2026, in connection with its process to explore strategic alternatives, the Company notified the holders

Original reporting
SEC EDGAR 8-K
Published Oct 1, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ADGM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

Low
01

Why it matters

The conversion of $776,111 of notes into ~5 million shares is a modest dilution event with no cash proceeds, likely exerting slight downward pressure on the stock.

02

Market read

A niche corporate action with limited trading relevance; primarily of interest to current shareholders and note holders.

03

What to watch

Potential downstream dilution and effect on existing shareholders' ownership percentages.

Relevance 5/10Novelty 6/10Timing: Oct 1, 2026 filing

Background

Adagio Medical Holdings filed an 8‑K reporting unregistered conversion of senior secured convertible notes into common stock under an alternate conversion price election.

Market effects

Sector

Minimal impact on medical device sector; isolated capital structure event.

Regional

No broader regional effect.

Global

Limited to investors holding ADGM securities.

Counterpoint

What could challenge this read

The conversion may signal limited confidence in future equity value, but could free up balance‑sheet capacity.

Key entities

  • company
    Adagio Medical Holdings, Inc.

    Issuer of the convertible notes and subject of the 8‑K filing.

  • person
    Deborah Kaster

    Chief Financial Officer and Chief Business Officer who signed the filing.

Read at source← All news

Related articles

SEP 16
$ADGMMedAI 8/10

Orange County Business Journal

Adagio Medical announced study results for its vClas Ultra cryoablation system, with the first patient treated by Dr. Roderick Tung. The study aims to support FDA approval for the first-generation device. Shares of Adagio (ADGM) were trading at 47 cents with a market cap of $10.6 million.

ocbj.com1 min
SEP 16
$ADGMMedAI 8/10

Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

Adagio Medical (ADGM) announced the first patient treated in its IDE study for the next-gen vCLAS Ultra System, designed for ventricular tachycardia (VT). The study aims to support a PMA supplement for the FDA. The system showed improved maneuverability and reduced ablation time in pre-clinical data. The company is focused on demonstrating the system's potential for faster, more efficient VT ablation procedures.

biospace.com2 min
AUG 11
$ADGMMed

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today anno

SEC EDGAR 8-K6 min
AUG 4
$ADGMMedAI 8/10

Adagio Medical Treats First Patient With Next-Generation VCLAS Ultra System; Stock Up

Adagio Medical Holdings (ADGM) said it treated its first patient with its next-generation vCLAS Ultra ultra-low temperature ablation system under FDA expanded access. The patient with non-ischemic cardiomyopathy and prior failed VT ablations was treated at the University of Pennsylvania. Adagio also noted IDE approval for its FULCRUM-VT trial and reported no VT recurrence two months later.

rttnews.com3 min
AUG 4
$ADGMMedAI 8/10

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Adagio Medical Holdings (Nasdaq: ADGM) said the FDA granted Expanded Access authorization for its next-generation vCLAS Ultra ULTA system, and clinicians at the Hospital of the University of Pennsylvania treated the first patient with ventricular tachycardia after prior failed ablations. The company expects IDE expansion of its FULCRUM-VT trial to assess the system for sustained monomorphic VT.

biospace.com4 min